Ajanta Pharma Limited (AJANTPHARM) - Total Assets
Based on the latest financial reports, Ajanta Pharma Limited (AJANTPHARM) holds total assets worth Rs56.72 Billion INR (≈ $613.45 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AJANTPHARM operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Ajanta Pharma Limited - Total Assets Trend (2005–2025)
This chart illustrates how Ajanta Pharma Limited's total assets have evolved over time, based on quarterly financial data. See Ajanta Pharma Limited (AJANTPHARM) net assets for net asset value and shareholders' equity analysis.
Ajanta Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Ajanta Pharma Limited's total assets of Rs56.72 Billion consist of 56.7% current assets and 43.3% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 3.5% |
| Accounts Receivable | Rs11.83 Billion | 23.6% |
| Inventory | Rs9.04 Billion | 18.0% |
| Property, Plant & Equipment | Rs18.92 Billion | 37.7% |
| Intangible Assets | Rs465.20 Million | 0.9% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Ajanta Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AJANTPHARM stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ajanta Pharma Limited's current assets represent 56.7% of total assets in 2025, a decrease from 61.1% in 2005.
- Cash Position: Cash and equivalents constituted 3.5% of total assets in 2025, up from 1.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 37.7% of total assets.
Ajanta Pharma Limited Competitors by Total Assets
Key competitors of Ajanta Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Ajanta Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.93 | 3.07 | 3.16 |
| Quick Ratio | 2.23 | 2.14 | 2.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs22.34 Billion | Rs18.86 Billion | Rs13.61 Billion |
Ajanta Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Ajanta Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.29 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 8.1% |
| Total Assets | Rs50.15 Billion |
| Market Capitalization | $4.68 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Ajanta Pharma Limited's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ajanta Pharma Limited's assets grew by 8.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ajanta Pharma Limited (2005–2025)
The table below shows the annual total assets of Ajanta Pharma Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs50.15 Billion ≈ $542.35 Million |
+8.12% |
| 2024-03-31 | Rs46.38 Billion ≈ $501.62 Million |
-0.87% |
| 2023-03-31 | Rs46.79 Billion ≈ $506.02 Million |
+15.37% |
| 2022-03-31 | Rs40.56 Billion ≈ $438.60 Million |
+7.33% |
| 2021-03-31 | Rs37.79 Billion ≈ $408.65 Million |
+13.86% |
| 2020-03-31 | Rs33.19 Billion ≈ $358.90 Million |
+23.09% |
| 2019-03-31 | Rs26.96 Billion ≈ $291.58 Million |
+10.11% |
| 2018-03-31 | Rs24.49 Billion ≈ $264.81 Million |
+34.34% |
| 2017-03-31 | Rs18.23 Billion ≈ $197.12 Million |
+23.04% |
| 2016-03-31 | Rs14.81 Billion ≈ $160.21 Million |
+29.23% |
| 2015-03-31 | Rs11.46 Billion ≈ $123.97 Million |
+20.75% |
| 2014-03-31 | Rs9.49 Billion ≈ $102.67 Million |
+32.18% |
| 2013-03-31 | Rs7.18 Billion ≈ $77.67 Million |
+10.70% |
| 2012-03-31 | Rs6.49 Billion ≈ $70.17 Million |
+24.25% |
| 2011-03-31 | Rs5.22 Billion ≈ $56.47 Million |
+5.47% |
| 2010-03-31 | Rs4.95 Billion ≈ $53.54 Million |
+6.96% |
| 2009-03-31 | Rs4.63 Billion ≈ $50.06 Million |
+28.61% |
| 2008-03-31 | Rs3.60 Billion ≈ $38.92 Million |
+34.15% |
| 2007-03-31 | Rs2.68 Billion ≈ $29.01 Million |
+11.41% |
| 2006-03-31 | Rs2.41 Billion ≈ $26.04 Million |
+11.02% |
| 2005-03-31 | Rs2.17 Billion ≈ $23.46 Million |
-- |
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more